BofA lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $8 from $10 and keeps a Buy rating on the shares, citing an updated cash position following the company’s Q3 update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- Buy Rating for Rocket Pharmaceuticals: Strategic Progress and Strong Financial Position Drive Positive Outlook
- Rocket Pharmaceuticals Reports Q3 2025 Financial Results
- Rocket Pharmaceuticals reports Q3 EPS (45c), consensus (52c)
- RCKT Upcoming Earnings Report: What to Expect?